ea0049gp187 | Pituitary & endocrine Tumours | ECE2017
Pivonello Rosario
, Kadioglu Pritam
, Bex Marie
, Devia Deyanira Gonzalez
, Boguszewski Cesar
, Yavuz Dilek Gogas
, Patino Heather
, Campigotto Federico
, Pedroncelli Alberto
, Fleseriu Maria
, Biller Beverly M K
, Feelders Richard
Background: Pasireotide is a multireceptor-targeted somatostatin analogue that predominantly binds to somatostatin receptor subtype 5 (SSTR5) and provides sustained control of urinary free cortisol (UFC) levels in some patients with Cushings disease (CD). Cabergoline is a dopamine D2 receptor agonist with efficacy in some patients with CD. Most corticotropinomas co-express SSTR5 and D2, providing rationale for combination treatment with pasireotide and cabergoline. Resul...